STAT+: Amgen wins FDA approval for first KRAS-blocking lung cancer drug

The Food and Drug Administration on Friday approved the first drug that benefits patients with lung cancer caused by a specific genetic mutation to a protein called KRAS, a target that for decades was considered to be “undruggable.”

The new medicine, a pill called Lumakras, was developed by Amgen.

Continue to STAT+ to read the full story…

STAT+: Amgen wins FDA approval for first KRAS-blocking lung cancer drug

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top